Document of The Week: Global Plan for Sharing Vaccines
An alliance of international health organizations are competing with the United States and other rich countries in an effort to secure vaccines for the world’s neediest.
With the Trump administration seeking to gobble up much of the world’s COVID-19 vaccine supplies for Americans, the World Health Organization and a coalition of governments and international health organizations have been straining to secure future stores of vaccines for the world’s neediest. The effort is led by Gavi, which is dedicated to making vaccines available to children around the world, and involves the Coalition for Epidemic Preparedness Innovations, which helps finance vaccine development and production, and the U.N. health agency.
With the Trump administration seeking to gobble up much of the world’s COVID-19 vaccine supplies for Americans, the World Health Organization and a coalition of governments and international health organizations have been straining to secure future stores of vaccines for the world’s neediest. The effort is led by Gavi, which is dedicated to making vaccines available to children around the world, and involves the Coalition for Epidemic Preparedness Innovations, which helps finance vaccine development and production, and the U.N. health agency.
The COVID-19 Vaccine Global Access (COVAX) Facility alliance aims to persuade governments to invest in the development and distribution of multiple vaccines to priority, vulnerable populations—including health workers, the elderly, and the ill—before distributing them universally. The effort is running into headwinds from bigger and sometimes richer countries, including China, the United States, and many in Europe, which are locking in their own agreements with major suppliers of vaccines.
On Friday, the French drugmaker Sanofi announced that the U.S. government would spend $2.1 billion to help the company and its British partner, GlaxoSmithKline, produce 100 million doses of an experimental coronavirus vaccine, bringing the total U.S. investment in experimental vaccines to more than $8 billion. Only a fraction of vaccine candidates are ever brought to market, and the United States, like many other countries, is betting on several companies to increase the odds that one or more will succeed.
As part of our Document of the Week series, Foreign Policy is publishing a copy of a June 11 internal draft technical design plan, outlining the COVAX Facility strategy for distributing vaccines around the world.
“The world urgently needs safe and efficacious COVID-19 vaccines to protect the most vulnerable, stop transmission and prevent resurgence of COVID-19,” according to the plan, which Foreign Policy cited in a previous report.
“Individual countries and groups of countries are already trying to address this challenge and secure vaccine[s] for their domestic or regional needs by entering into bilateral agreements with manufacturers. However, going down this pathway with a siloed and disaggregated approach will not be effective or efficient. The competition for vaccine candidate would lead to a global bidding frenzy, driving up pricing as countries ‘panic buy.’”
Officials familiar with the effort to secure government investments in the COVAX Facility say the goal is to conclude negotiations by the end of August. But a number of sticking points remain, including who will decide who gets the vaccines—or, as one official put it, “who calls the shots on the shots.”
Read More
The Coronavirus Pandemic Will Transform How Vaccines Are Made
The COVID-19 crisis could enable the improvement of the global vaccine system for all diseases. Here’s how that could happen.
Will China’s Elite Ever Rise Up?
Inside the world of China’s richest players.
A Tale of Two Germanies
Thirty-three years after reunification, the country’s wounds are rawer than many would like to admit.
Colum Lynch was a staff writer at Foreign Policy between 2010 and 2022. Twitter: @columlynch
Read More
The Coronavirus Pandemic Will Transform How Vaccines Are Made
The COVID-19 crisis could enable the improvement of the global vaccine system for all diseases. Here’s how that could happen.
Will China’s Elite Ever Rise Up?
Inside the world of China’s richest players.
A Tale of Two Germanies
Thirty-three years after reunification, the country’s wounds are rawer than many would like to admit.
More from Foreign Policy
No, the World Is Not Multipolar
The idea of emerging power centers is popular but wrong—and could lead to serious policy mistakes.
America Prepares for a Pacific War With China It Doesn’t Want
Embedded with U.S. forces in the Pacific, I saw the dilemmas of deterrence firsthand.
America Can’t Stop China’s Rise
And it should stop trying.
The Morality of Ukraine’s War Is Very Murky
The ethical calculations are less clear than you might think.
Sign up for World Brief
FP’s flagship evening newsletter guiding you through the most important world stories of the day. Delivered weekdays.
By submitting your email, you agree to the Privacy Policy and Terms of Use and to receive email correspondence from us. You may opt out at any time.